70311-27-2

Basic information

• Product Name: 3-(2-METHOXY-PHENYL)-PROPIONIC ACID ETHYL ESTER
• Synonyms: 3-(2-METHOXY-PHENYL)-PROPIONIC ACID ETHYL ESTER
• CAS NO: 70311-27-2
• Molecular Formula: C₁₂H₁₆O₃
• Molecular Weight: 208.25
• Mol File: 70311-27-2.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 280.7°C at 760 mmHg
• Flash Point: 112.8°C
• Appearance: /
• Density: 1.045g/cm³
• Vapor Pressure: 0.00373mmHg at 25°C
• Refractive Index: 1.495
• CAS DataBase Reference: 3-(2-METHOXY-PHENYL)-PROPIONIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2-METHOXY-PHENYL)-PROPIONIC ACID ETHYL ESTER(70311-27-2)
• EPA Substance Registry System: 3-(2-METHOXY-PHENYL)-PROPIONIC ACID ETHYL ESTER(70311-27-2)

Safety Data

• Hazardous Substances Data: 70311-27-2(Hazardous Substances Data)

Usage

InChI:InChI=1/C12H16O3/c1-3-15-12(13)9-8-10-6-4-5-7-11(10)14-2/h4-7H,3,8-9H2,1-2H3

Upstream product

• 578-57-4 2-bromoanisole 
• 140-88-5 ethyl acrylate 
• 33877-05-3 ethyl 3-(2-methoxyphenyl)acrylate 
• 6342-77-4 2-methoxy-benzenepropanoic acid 
• 105-58-8 Diethyl carbonate 
• 7335-26-4 ethyl 2-methoxybenzoate 
• 606-45-1 2-methoxybenzoic acid methyl ester 
• 135-02-4 ortho-anisaldehyde 
• 6099-03-2 3-(2'-methoxyphenyl)propenoic acid 
• 3054-95-3 acrylaldehyde diethyl acetal 
• 529-28-2 4-iodoanisol 
• 41607-95-8 3-(2-methoxy-phenyl)-3-oxo-propionic acid ethyl ester 
• 24393-54-2 ethyl 3-(2-methoxyphenyl)prop-2-enoate 
• 612-16-8 (2-methoxyphenyl)methanol 

Downstream Products

• 6342-77-4 2-methoxy-benzenepropanoic acid 
• 408308-07-6 5-(2'-methoxyxyphenyl)pentanoic acid 
• 643746-88-7 5-(2-methoxyphenyl)pentanoic acid ethyl ester 
• 14374-55-1 5-(2-methoxyphenyl)pentan-1-ol 
• 150598-13-3 4-[(5-Bromopentyl)oxy]-3-(3-ethoxy-3-oxopropyl)-γ-oxo-benzenebutanoic Acid Ethyl Ester 
• 150598-58-6 3-(3-ethoxy-3-oxopropyl)-4-hydroxy-γ-oxobenzenebutanoic acid ethyl ester 
• 635-46-1 1,2,3,4-tetrahydroisoquinoline 
• 21863-32-1 N-benzyltetrahydroquinoline 
• 101581-87-7 N-phenylmethyl-3-(2-methoxyphenyl)propylamine 
• 18655-51-1 2-(3-Aminopropyl)-1-methoxybenzene 
• 146253-19-2 3-(2-methoxyphenyl)propyl methanesulfonate 
• 154585-02-1 4-(2-methoxyphenyl)butylamine 
• 60740-67-2 1-benzyl-2,3,4,5-tetrahydro-1H-benzo[b]azepine 
• 150598-55-3 3-(3-Ethoxy-3-oxopropyl)-4-methoxy-δ-oxobenzenepentanoic Acid 

Relevant articles and documents

Nucleophilic Amination of Methoxy Arenes Promoted by a Sodium Hydride/Iodide Composite

A method for the nucleophilic amination of methoxy arenes was established by using sodium hydride (NaH) in the presence of lithium iodide (LiI). This method offers an efficient route to benzannulated nitrogen heterocycles. Mechanistic studies showed that the reaction proceeds through an unusual concerted nucleophilic aromatic substitution.

The unexpected kinetic effect of enzyme mixture: The case of enzymatic esterification

During the studies towards synthesis of carboxylic acids esters, using ethyl carbonate and carboxylic acid as substrates, we found that different single enzyme systems provide model ethyl 3-phenylpropanoate in very low yield. Systematic studies proved tha

1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS

The invention relates to novel 1,6-disubstituted pyrazolopyrimidinones, Formula (I) with Hc is a mono-, bi- or tricyclic heterocyclyl group, the ring members of which are carbon atoms and at least 1, preferably 1, 2 or 3, heteroatom(s), which are selected from the group of nitrogen, oxygen and sulphur, which is in the form of -S(O)r - with r being 0, 1 or 2, and - said heterocyclyl group is or comprises 1 non-aromatic, saturated, or partly unsaturated monocyclic ring which comprises at least 1 heteroatom as ring member and - said heterocyclyl group is bound to the scaffold by said 1 non- aromatic, saturated, or partly unsaturated monocyclic ring which comprises at least 1 heteroatom as ring member. According to one aspect of the invention the new compounds are for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments for the treatment of Alzheimer's disease.